Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BELLICUM PHARMACEUTICALS, INCBLCM · Entity 107976 | Director | January 03, 2023 | January 20, 2023 |
| INCYTE CORPINCY · Entity 3182 | EVP, Chief Scientific Officer | July 16, 2018 | July 18, 2018 |
| Rapport Therapeutics, Inc.RAPP · Entity 4394 | Director | June 10, 2026 | June 10, 2026 |
| Tango Therapeutics, Inc.TNGX · Entity 1497 | Director | June 06, 2023 | June 09, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BELLICUM PHARMACEUTICALS, INC
Report date January 03, 2023 · Filed January 20, 2023 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 146,951 |
Reported balance
After 2023-01-03 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2023-01-03 · Exercise / conversion · Acquired 80,968 · Balance 146,951 F1: This amendment is being filed to correct the mathematical error in the amount of securities acquired and the amount of securities beneficially owned following reported transaction on the original Form 4 filed with the SEC on January 5, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: This amendment is being filed to correct the mathematical error in the amount of securities acquired and the amount of securities beneficially owned following reported transaction on the original Form 4 filed with the SEC on January 5, 2023.
INCYTE CORP
Report date July 16, 2018 · Filed July 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,571 |
Reported balance
After 2018-07-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-07-16 · Tax withholding · Disposed 448 · Balance 34,571 F1: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.
F2: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
Rapport Therapeutics, Inc.
Report date June 10, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.21 · Expires 2036-06-10 | Direct | 15,200 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 15,200 · Balance 15,200 F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.
Tango Therapeutics, Inc.
Report date June 06, 2023 · Filed June 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,000 |
Reported balance
After 2023-06-06 transaction · row 1
1 source rowRow 1 · 2023-06-06 · Grant · Acquired 5,000 · Balance 5,000 F1: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 6, 2024 and (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.55 · Expires 2033-06-06 | Direct | 30,000 |
Reported balance
After 2023-06-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-06 · Grant · Acquired 30,000 · Balance 30,000 F2: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year beginning on July 6, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 6, 2024 and (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F2: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year beginning on July 6, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CARGO Therapeutics, Inc.
Report date August 19, 2025 · Filed August 19, 2025
Section 16 reporting ended · disclosed 2025-08-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.35 · Expires 2035-06-17 | Direct | 0 |
Reported balance
After 2025-08-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-08-19 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $4.379 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] F3: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $4.379 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2]
F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]
F3: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 10, 2026 21:25 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | GrantStock Option (Right to Buy) · Derivative | 15,200 | $0.00 Strike: $35.21 | $0.00 |
DisclosureSEC source: 0001193125-26-266090 · ownership.xml · derivative · entry 1 Huber Reid M · CIK 0001607052 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,200 Underlying: Common Stock · 15,200 shares Expires 2036-06-10 F1 · derivative.exercise_date: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| September 12, 2025 Filed Sep 15, 2025 20:05 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | PurchaseCommon Stock | 20,400 | $24.48 | $499,373.64 |
DisclosureSEC source: 0001193125-25-203540 · ownership.xml · nonDerivative · entry 1 Huber Reid M · CIK 0001607052 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,400 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $24.23 to $24.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. Read SEC document |
| August 19, 2025 Filed Aug 19, 2025 20:38 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $4.35 | Not disclosed |
DisclosureSEC source: 0001610717-25-000299 · form4.xml · derivative · entry 1 Huber Reid M · CIK 0001607052 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2035-06-17 F1 · price: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $4.379 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2] F2 · price: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] F3 · price: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration. F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $4.379 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] F3 · derivative.exercise_date: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 21:43 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001610717-25-000249 · form4.xml · derivative · entry 1 Huber Reid M · CIK 0001607052 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-06-17 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) the one year anniversary of June 18, 2025 or (ii) the next Annual Meeting following June 18, 2025, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 20:15 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | GrantStock Option (Right to Buy) · Derivative | 21,850 | $0.00 Strike: $10.95 | $0.00 |
DisclosureSEC source: 0000950170-25-087899 · ownership.xml · derivative · entry 1 Huber Reid M · CIK 0001607052 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,850 Underlying: Common Stock · 21,850 shares Expires 2035-06-17 F1 · derivative.exercise_date: The shares underlying this option shall vest upon the earlier of (i) June 17, 2026 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:28 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | GrantStock Option (Right to Buy) · Derivative | 23,742 | $0.00 Strike: $19.17 | $0.00 |
DisclosureSEC source: 0001610717-24-000299 · form4.xml · derivative · entry 1 Huber Reid M · CIK 0001607052 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,742 Underlying: Common Stock · 23,742 shares Expires 2034-06-03 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 4, 2024 (the "Vesting Commencement Date") or (ii) the next Annual Meeting following June 4, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 09, 2023 Filed Nov 13, 2023 23:45 UTC | CARGO Therapeutics, Inc. CRGX · Entity 76319 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000345 · form4.xml · derivative · entry 1 Huber Reid M · CIK 0001607052 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-11-08 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from November 10, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
| June 06, 2023 Filed Jun 9, 2023 01:34 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0000899243-23-015015 · doc4.xml · derivative · entry 2 Huber Reid M · CIK 0001607052 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-06-06 F2 · derivative.exercise_date: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year beginning on July 6, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| June 06, 2023 Filed Jun 9, 2023 01:34 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-015015 · doc4.xml · nonDerivative · entry 1 Huber Reid M · CIK 0001607052 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 6, 2024 and (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 13:12 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionCommon Stock | 87,196 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-000420 · wf-form4_167294231854390.xml · nonDerivative · entry 1 Huber Reid M · CIK 0001607052 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on January 3, 2024, the one-year anniversary of the grant date. Read SEC document |
| January 03, 2023 Filed Jan 20, 2023 14:24 UTC Amendment | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionCommon Stock | 80,968 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-001321 · wf-form4a_167424267625682.xml · nonDerivative · entry 1 Huber Reid M · CIK 0001607052 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This amendment is being filed to correct the mathematical error in the amount of securities acquired and the amount of securities beneficially owned following reported transaction on the original Form 4 filed with the SEC on January 5, 2023. F1 · balance_after: This amendment is being filed to correct the mathematical error in the amount of securities acquired and the amount of securities beneficially owned following reported transaction on the original Form 4 filed with the SEC on January 5, 2023. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 10:29 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionCommon Stock | 46,489 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-024218 · wf-form4_166212897072850.xml · nonDerivative · entry 1 Huber Reid M · CIK 0001607052 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,983 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on September 1, 2023, the one-year anniversary of the grant date. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 14:45 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001628280-22-017337 · wf-form4_165540513956658.xml · derivative · entry 1 Huber Reid M · CIK 0001607052 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · Not disclosed shares Expires 2032-06-14 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in full on the one-year anniversary of the grant date. Read SEC document |
| June 08, 2022 Filed Jun 28, 2022 20:27 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0000899243-22-024396 · doc4.xml · derivative · entry 1 Huber Reid M · CIK 0001607052 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year from June 8, 2022, subject to the Reporting Person's continuous service on the board of directors as of each such vesting date. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 09:51 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionRestricted Stock Units · Derivative | 19,494 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-000416 · wf-form4_164148067397164.xml · derivative · entry 2 Huber Reid M · CIK 0001607052 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,494 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer common stock. F2 · derivative.exercise_date: The RSUs vest in full upon the one year anniversary of grant date on January 4, 2021. F2 · derivative.expiration_date: The RSUs vest in full upon the one year anniversary of grant date on January 4, 2021. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 09:51 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionCommon Stock | 19,494 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-000416 · wf-form4_164148067397164.xml · nonDerivative · entry 1 Huber Reid M · CIK 0001607052 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer common stock. Read SEC document |
| June 15, 2021 Filed Jul 7, 2021 20:27 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $3.05 | $0.00 |
DisclosureSEC source: 0001209191-21-045944 · doc4.xml · derivative · entry 1 Huber Reid M · CIK 0001607052 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2031-06-14 Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 18:37 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantRestricted Stock Units · Derivative | 19,494 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-000097 · wf-form4_160988984730933.xml · derivative · entry 1 Huber Reid M · CIK 0001607052 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,494 Underlying: Common Stock · 19,494 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of BLCM common stock. F2 · derivative.exercise_date: The RSUs will vest in full upon the one year anniversary of the date of grant. F2 · derivative.expiration_date: The RSUs will vest in full upon the one year anniversary of the date of grant. Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 16:47 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $8.42 | $0.00 |
DisclosureSEC source: 0001628280-20-009547 · wf-form4_159234044255883.xml · derivative · entry 1 Huber Reid M · CIK 0001607052 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2030-06-14 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in full on the one-year anniversary of the grant date. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 16:04 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001358403-19-000092 · wf-form4_156054263689561.xml · derivative · entry 1 Huber Reid M · CIK 0001607052 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in full on the one-year anniversary of the grant date. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 20:28 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 448 | $70.19 | $31,445.12 |
DisclosureSEC source: 0001209191-18-043040 · doc4.xml · nonDerivative · entry 1 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,571 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 21:04 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 284 | $68.28 | $19,391.52 |
DisclosureSEC source: 0001209191-18-041730 · doc4.xml · nonDerivative · entry 1 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,019 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 9,415 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 21:04 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 22,772 | $0.00 Strike: $68.62 | $0.00 |
DisclosureSEC source: 0001209191-18-041730 · doc4.xml · derivative · entry 2 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,772 Underlying: Common Stock · 22,772 shares Expires 2028-07-01 F3 · derivative.exercise_date: Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 16:31 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $9.80 | $0.00 |
DisclosureSEC source: 0001358403-18-000062 · wf-form4_152935388699875.xml · derivative · entry 1 Huber Reid M · CIK 0001607052 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in equal monthly installments until the Issuer's 2019 Annual Meeting of stockholders. Read SEC document |
| February 21, 2018 Filed Feb 22, 2018 21:23 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 1,958 | $85.55 | $167,506.90 |
DisclosureSEC source: 0001209191-18-012416 · doc4.xml · nonDerivative · entry 2 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,183 F2 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $85.11 - $86.27. F4 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F5 · balance_after: Includes an aggregate of 10,294 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 21:23 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 1,064 | $86.03 | $91,535.92 |
DisclosureSEC source: 0001209191-18-012416 · doc4.xml · nonDerivative · entry 1 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,141 F1 · shares: Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. Read SEC document |
| January 24, 2018 Filed Jan 25, 2018 21:41 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 21,167 | $0.00 Strike: $95.34 | $0.00 |
DisclosureSEC source: 0001209191-18-005396 · doc4.xml · derivative · entry 2 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,167 Underlying: Common Stock · 21,167 shares Expires 2028-01-23 F2 · derivative.exercise_date: Beginning January 24, 2018, options become exercisable in full on January 24, 2022. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 21:41 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 12,128 | $0.00 Strike: $94.63 | $0.00 |
DisclosureSEC source: 0001209191-18-005396 · doc4.xml · derivative · entry 1 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,128 Underlying: Common Stock · 12,128 shares Expires 2028-01-22 F1 · derivative.exercise_date: Beginning January 23, 2018, options become exercisable in 37 installments, with the first 25.00% vesting on July 5, 2018 and the remainder vesting monthly over three years. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:01 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 696 | $98.01 | $68,214.96 |
DisclosureSEC source: 0001209191-17-063857 · doc4.xml · nonDerivative · entry 1 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,205 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: Includes an aggregate of 13,316 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 20:24 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 692 | $123.15 | $85,219.80 |
DisclosureSEC source: 0001209191-17-052975 · doc4.xml · nonDerivative · entry 1 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,862 F1 · shares: Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 13,316 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 20:46 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,128 | $0.00 Strike: $128.34 | $0.00 |
DisclosureSEC source: 0001209191-17-044406 · doc4.xml · derivative · entry 2 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,128 Underlying: Common Stock · 12,128 shares Expires 2027-07-04 F3 · derivative.exercise_date: Beginning July 5, 2017, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 20:46 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 3,517 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-044406 · doc4.xml · nonDerivative · entry 1 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,554 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Mr. Huber's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Includes an aggregate of 11,187 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 14, 2017 Filed Jun 15, 2017 16:39 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0001358403-17-000095 · wf-form4_149755915389119.xml · derivative · entry 1 Huber Reid M · CIK 0001607052 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-13 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in equal monthly installments until the Issuer's 2018 Annual Meeting of stockholders. Read SEC document |
| May 08, 2017 Filed May 9, 2017 20:38 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 8,577 | $119.21 | $1,022,464.17 |
DisclosureSEC source: 0001209191-17-030962 · doc4.xml · nonDerivative · entry 2 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,037 F2 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $117.45 - $121.72. F4 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F5 · balance_after: Includes an aggregate of 11,187 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| May 05, 2017 Filed May 9, 2017 20:38 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 7,732 | $125.00 | $966,500.00 |
DisclosureSEC source: 0001209191-17-030962 · doc4.xml · nonDerivative · entry 1 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,614 F1 · shares: Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:56 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 2,008 | $131.88 | $264,815.04 |
DisclosureSEC source: 0001209191-17-015945 · doc4.xml · nonDerivative · entry 1 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,262 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: Includes an aggregate of 27,496 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:52 UTC | INCYTE CORP INCY · Entity 3182 | GrantIncentive Stock Option (right to buy) · Derivative | 879 | $0.00 Strike: $113.64 | $0.00 |
DisclosureSEC source: 0001209191-17-004550 · doc4.xml · derivative · entry 3 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 879 Underlying: Common Stock · 879 shares Expires 2027-01-16 F2 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in full on January 17, 2021. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:52 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 17,986 | $0.00 Strike: $113.64 | $0.00 |
DisclosureSEC source: 0001209191-17-004550 · doc4.xml · derivative · entry 2 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,986 Underlying: Common Stock · 17,986 shares Expires 2027-01-16 F2 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in full on January 17, 2021. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:52 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 19,091 | $0.00 Strike: $113.64 | $0.00 |
DisclosureSEC source: 0001209191-17-004550 · doc4.xml · derivative · entry 1 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,091 Underlying: Common Stock · 19,091 shares Expires 2027-01-16 F1 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in 37 installments, with the first 25.00% vesting on July 15, 2017 and the remainder vesting monthly over three years. Read SEC document |
| January 09, 2017 Filed Jan 11, 2017 21:21 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 11,739 | $113.55 | $1,332,963.45 |
DisclosureSEC source: 0001209191-17-003360 · doc4.xml · nonDerivative · entry 1 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,185 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: Includes an aggregate of 27,496 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 21:34 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 2,715 | $109.95 | $298,514.25 |
DisclosureSEC source: 0001209191-16-149366 · doc4.xml · nonDerivative · entry 1 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,924 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: Includes an aggregate of 27,496 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| October 07, 2016 Filed Oct 11, 2016 20:37 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 11,709 | $0.00 Strike: $18.32 | $0.00 |
DisclosureSEC source: 0001209191-16-145584 · doc4.xml · derivative · entry 3 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,709 shares Expires 2020-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| October 07, 2016 Filed Oct 11, 2016 20:37 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 11,709 | $96.40 | $1,128,747.60 |
DisclosureSEC source: 0001209191-16-145584 · doc4.xml · nonDerivative · entry 2 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,601 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $95.24 - $97.00 F4 · balance_after: Includes an aggregate of 27,496 shares of common stock issuable to previously reported restricted stock units that have not vested. Read SEC document |
| October 07, 2016 Filed Oct 11, 2016 20:37 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 11,709 | $18.32 | $214,508.88 |
DisclosureSEC source: 0001209191-16-145584 · doc4.xml · nonDerivative · entry 1 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2016 Filed Feb 28, 2017 21:56 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 1,090 | $121.95 | $132,925.50 |
DisclosureSEC source: 0001209191-17-015338 · doc4.xml · nonDerivative · entry 2 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,270 F3 · shares: Represents shares withheld to satisfy tax withholding obligations with respect to vested performance shares. F2 · balance_after: Includes an aggregate of 27,496 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| February 14, 2016 Filed Feb 28, 2017 21:56 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 3,098 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-015338 · doc4.xml · nonDerivative · entry 1 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,360 F1 · shares: Represents shares acquired upon vesting of performance shares. Each performance share represented the right to receive one or more shares of common stock based on, and subject to, the achievement of certain clinical and revenue milestones as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person was entitled to receive ranged from 0% to 125% of the number of performance shares awarded. Performance share milestones were achieved at the 100% level. F2 · balance_after: Includes an aggregate of 27,496 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.